1 / 8

GAVI CSO involvement in Technology Transfer: Developments to date & decision on next steps

GAVI CSO involvement in Technology Transfer: Developments to date & decision on next steps. Technology transfer (TT): Quick background.

tracy
Télécharger la présentation

GAVI CSO involvement in Technology Transfer: Developments to date & decision on next steps

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GAVI CSO involvement in Technology Transfer:Developments to date & decision on next steps

  2. Technology transfer (TT): Quick background • Definition: the process of transferring skills, knowledge, technologies, methods of manufacturing and facilities to ensure that scientific and technological developments are accessible to a wider range of users who can then further develop and exploit the technology into new products, processes, applications, materials or services. • Public-private, private-public, private-private, public-public • Can play a central role in the economic and social transformation of countries • Can lead to improvement in the quality of production, generation of new knowledge, improvement in living standards and productivity among others (Torlak, 2004) • TT of manufacturing processes for vaccines sometimes viewed as the preferred path for providing access to affordable vaccines in developing countries • Requires further understanding of the necessary elements for sustainable success • TT for vaccine production generally more complex than for other pharmaceuticals, especially for live vaccines

  3. TT session: GAVI Partners Forum • IFPMA, DCVMN, GAVI CSO and MOH of Bangladesh jointly organized workshop on technology transfers • MSF spoke on behalf of CSO Constituency (Dr. ManicaBalasegaram) • Main topic areas addressed: • Types of TT and history, step-wise collaborative approach and the role of industry. Originators and recipients perspectives were shared. • Enabling conditions of TT and limitations of where it can be considered. Roles of partners were outlined. • The possible role of TT in delivery better adapted vaccines for GAVI-eligible countries. • Lessons learned and ways forward for continuous sustainable access to high quality, innovative and affordable vaccines.

  4. …since then… • IFPMA and DCVMN keen to continue collaboration, bringing in WHO (and possibly nudging GAVI Board to consider TT as part of the package of TA to graduating countries, where appropriate) • April 2013 informal meeting to discuss potential next steps (CSO reps: MSF and IFRC on behalf of the Constituency) • IFPMA, DCVMN and CSO reps agree to go back to their decision-making bodies for agreement on next steps based on ideas outlined in follow-up document…

  5. Proposed future focuses • Overarching goal and theme of the proposed future joint work: “Increasing success of vaccines technology transfers and exploiting effective alternatives” • Develop a TT “pre-requisites for success” check list following an all-inclusive review and analysis of available data and published literature and define key conditions for success from the manufacturers’ perspective and the recipient countries’ perspective • Consider repeating TT workshop in a larger venue • Develop recommendations to GAVI Alliance for role in TT

  6. CSO key points made to-date • GAVI graduating countries could become a focus for the effort – both in terms of technical and advocacy conversations • Important to define and communicate both TT incentives and disincentives (eg. size of the countries / markets, NRAs capabilities, political stability, etc.) • Both technical (eg. manufacturing and licensing capacity, upholding quality standards) and business (eg. viable business model(s) and market(s), economies of scale and sustainability in time) “mentoring” and mechanisms will be required and should always take place in parallel. • Consider how TT could deliver better ‘adapted’ products that are more suitable for GAVI-eligible countries; as well as reduce vaccine prices by stimulating competition. • GAVI and other global health stakeholders should think about incentivizing technology transfer in middle-income countries. • Recipient’s country MOH perspective (and other ministries) and understanding of enabling conditions, coupled with the political will to meet such conditions, absolutely crucial in achieving success. • Important to involve high-level MOH officials in future dialogue and experience sharing (BGD was a good example at GAVI PF).

  7. Next steps and proposed work plan • Agreement and endorsement of the proposal by IFPMA, DCVMN and CSOs: Q2 2013 • Mapping and evaluation of complementary work streams and opportunities for communication: Q4 2013 • Reach out to WHO / HIS, GPEI and GAVI: Q4 2013 • Data analysis and checklist commissioned: Q1 2013 (subject to available funding from partners - consider joint IFPMA / DCVMN / CSO (?) funding/contributions) • Advocacy materials development: Q1/2, 2014 (subject to available funding from partners) • Profiling at World Immunization Week: April 2014 • Reach-out to GAVI members (Board, Advisors): Q2, 2014 • Other activities and partners to be involved: TBD

  8. Discussion • Does the CSO SC see value in this proposed project? • What are the possible concerns/risks with engaging the CSO Constituency in this initiative? • How do we see this initiative linking to the GAVI Alliance? What do we foresee as the end goal for this initiative? • If we wish to pursue the initiative, which CSO members will take it forward? (human resources required)

More Related